Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Amortizatization of Intangibles: 2011-2024

Historic Amortizatization of Intangibles for Iovance Biotherapeutics (IOVA) over the last 10 years, with Dec 2024 value amounting to $21.2 million.

  • Iovance Biotherapeutics' Amortizatization of Intangibles rose 5.45% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year increase of 21.20%. This contributed to the annual value of $21.2 million for FY2024, which is 81.06% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Amortizatization of Intangibles of $21.2 million as of FY2024, which was up 81.06% from $11.7 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Amortizatization of Intangibles ranged from a high of $21.2 million in FY2024 and a low of $7.6 million during FY2020.
  • Over the past 3 years, Iovance Biotherapeutics' median Amortizatization of Intangibles value was $11.8 million (recorded in 2022), while the average stood at $14.9 million.
  • In the last 5 years, Iovance Biotherapeutics' Amortizatization of Intangibles decreased by 0.97% in 2023 and then skyrocketed by 81.06% in 2024.
  • Iovance Biotherapeutics' Amortizatization of Intangibles (Yearly) stood at $7.6 million in 2020, then skyrocketed by 43.54% to $10.9 million in 2021, then increased by 8.80% to $11.8 million in 2022, then decreased by 0.97% to $11.7 million in 2023, then surged by 81.06% to $21.2 million in 2024.